PORTLAND, Oregon, October 21, 2015 /PRNewswire/ --
Sexually Transmitted Diseases (STDs) are also known as Venereal diseases (VDs) or Sexually Transmitted Infections (STIs). A variety of methods have been employed for diagnosis of STDs that differ based on the type of disease. The objective of this report is to provide an in-depth understanding of diagnostic tests of STDs. The market diagnostic testing of STDs was valued at $96.7 billion in 2013 with a corresponding test volume of 4,204 million. Rising incidences of fatal STDs, corresponding high-economic burden and consequent implementation of Provider-Initiated Counselling and Testing (PICT) and Client-Initiated Counselling and Testing (CICT) drive the growth of STD testing market; however, inadequate infrastructure provisions such as labs, equipment and supplies, lack of trained laboratory personnel in the secluded geographic locations (for example, West African countries) and stigma associated with voluntary testing are likely to be the major restraints of the market. However, global initiatives along with development in healthcare infrastructure will provide future growth thrust for the market. Thus, the diagnostic testing of STDs is estimated to grow at a CAGR of 8.5% over the forecast period 2014-2020 to reach market size of $167.4 billion in 2020. The test volume will rise to 5,520 million in 2020.
The global market for diagnostic testing of STDs is segmented based on types of STDs - Chlamydia testing, Gonorrhoea testing, Syphilis testing, Human Immunodeficiency Virus (HIV) testing, Herpes Simplex Virus (HSV) testing, Human Papilloma Virus (HPV) testing and Chancroid testing. HIV testing, which is the third largest STD testing market, would grow at a CAGR of 10.9% during 2014 - 2020.
Based on point of testing, market is segmented in to laboratories and point-of-care (PoC). Currently, laboratories perform bulk of the tests and would continue to hold larger share of the market, both in terms of volume and revenue. PoCs will grow at constant rate during the forecast period.
The report also provides market size and forecast for testing devices used for carrying such tests. The market for STD testing devices was valued at $7.7 billion in 2013 with laboratory testing devices accounted for the most of the market and PoC devices shall grow at fastest rate.
As elaborated earlier, many healthcare institutions provide diagnostic testing services for STDs, such as specialized STD clinics, Genito-Urinary Medicine (GUM) clinics along with general hospitals, government laboratories and private diagnostic centres. The afore-mentioned thus constitute key market participants of the global diagnostic testing of STDs market. Along with the testing service providers, many companies provide devices such as laboratory instruments and POC testing kits/devices for STDs; for instance, Roche Holdings AG. Roche Holdings AG recently announced an immunoassay diagnostic test for the detection of Syphilis during a routine clinical practice. Other companies profiled in the report are BioMerieux, Hologic Inc., Becton Dickinson & Company, Cepheid Inc., Danaher Corporation, Affymetrix, Alere Inc., Abbott Laboratories, Bio-Rad Laboratories Inc., and DiaSorin.
Enquiry about report visit @ http://www.bigmarketresearch.com/diagnostic-testing-stds-market
Browse Similar Report:
2016 Emerging US Sexually-Transmitted Disease Testing Market
US sexually-transmitted disease testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and strategic profiles of leading suppliers.
The report presents detailed analysis of the STD market in the US, Current scientific views on epidemiology and etiology are presented for Chancroid, Chlamydia, Gonorrhea, Herpes, HPV, and Syphilis. The report provides test volume and sales forecasts and market segment, including: Hospitals, Commercial/Private Labs, Physician Offices, Public Health Labs
Get more details @ http://www.bigmarketresearch.com/2016-emerging-us-sexually-transmitted-disease-testing-chancroid-chlamydia-gonorrhea-herpes-hpv-syphilis-supplier-shares-by-test-competitive-strategies-country-volume-and-sales-segment-forecasts-market
Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2015
This report provides comprehensive information on the therapeutic development for Female Hypoactive Sexual Desire Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Hypoactive Sexual Desire Disorder and special features on late-stage and discontinued projects
With the arsenal of different search reports, we help you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.
With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
Direct :+ 1-503-894-6022
Toll Free :+ 1-800-910-6452
SOURCE Big Market Research